MAR-Autism Diagnostic Test

About MARAbio

MARAbio is a private, pre-revenue biotech company developing a diagnostic and therapeutic platform for Maternal Autoantibody Related Autism (MARA), an immune-mediated subtype estimated to represent up to 20% of autism cases. Its core asset is a highly predictive maternal blood test designed for use prior to or early in pregnancy, enabling early intervention. The company is leveraging this diagnostic foundation to build a pipeline of proprietary therapeutic antibodies aimed at blocking the pathogenic autoantibodies, positioning itself at the intersection of precision diagnostics and targeted immunology.

Therapeutic Areas